---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-159134"
form_type: "8-K"
ticker: null
cik: "0001501756"
company_name: "Adverum Biotechnologies, Inc."
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:02:08.456561+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Adverum appoints Rabia Ozden as CMO, Szilard Kiss to board, effective June 10

## Summary
- Rabia Gurses Ozden, M.D. appointed Chief Medical Officer effective June 10, 2024.
- Ozden resigned from the Board and R&D Committee effective same date.
- Szilard Kiss, M.D. appointed as Class III director; expected to join R&D Committee.
- Kiss is a retina specialist, professor at Weill Cornell, and CMO of Blue Gen Therapeutics.

## SEC filing metadata
- accession: 0001193125-24-159134
- form_type: 8-K
- cik: 0001501756
- company_name: Adverum Biotechnologies, Inc.
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/d849862d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-159134
- JSON: https://secwatch.observer/filing/0001193125-24-159134.json
- Plain text: https://secwatch.observer/filing/0001193125-24-159134.txt

## Key facts
- Executive change
  Rabia Gurses Ozden, M.D. was appointed as Chief Medical Officer at Adverum Biotechnologies, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: appointed Rabia Gurses Ozden, M.D. as the Company’s Chief Medical Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm
- Executive change
  Rabia Gurses Ozden, M.D. resigned as Director at Adverum Biotechnologies, Inc..
  - Action: resigned
  - Role: Director
  source text: Dr. Ozden notified the Board of her decision to resign from the Board and the Research and Development Committee of the Board, effective June 10, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm
- Executive change
  Szilárd Kiss, M.D. was appointed as Director at Adverum Biotechnologies, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Szilárd Kiss, M.D. as a director to fill the vacancy on the Board created by Dr. Ozden’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000119312524159134/0001193125-24-159134-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.